KMID : 0363220200580060389
|
|
Korean Journal of Dermatology 2020 Volume.58 No. 6 p.389 ~ p.396
|
|
Efficacy and Safety of Ixekizumab for the Treatment of Moderate to Severe Psoriasis in Korea
|
|
Won Sang-Hyeon
Shin Ki-Hyuk Kim Hoon-Soo Ko Hyun-Chang Kim Moon-Bum Kim Byung-Soo
|
|
Abstract
|
|
|
Background: Ixekizumab is a humanized IgG4 monoclonal antibody that selectively binds to the IL-17A cytokine and inhibits its interaction with the IL-17 receptor. It has emerged as an effective treatment for moderate to severe psoriasis. However, to date, there are no real-world data for the use of ixekizumab in the treatment of psoriasis in Korean patients.
Objective: To evaluate the effectiveness and safety of ixekizumab in the treatment of moderate to severe psoriasis in Korean patients.
Methods: This was a retrospective single-center study. Thirty psoriasis patients who were treated with ixekizumab were analyzed. All patients¡¯ medical records, Psoriasis Area and Severity Index (PASI) score, body surface area (BSA), Physicians¡¯ Global Assessment (PGA), and adverse events were investigated.
Results: A significant reduction in mean (¡¾standard deviation) baseline PASI score (14.1¡¾2.6) was detected at 4 weeks of ixekizumab therapy (3.8¡¾2.7, p£¼0.001), with a further improvement at weeks 12 and 24 (0.9¡¾0.7 and 0.5¡¾0.5, respectively) (p£¼0.001). Our analysis showed that 100%, 87.5%, and 50% of patients achieved PASI 75, 90, and 100 responses, respectively, after 48 weeks of therapy. However, nine patients (30%) experienced a mild adverse event such as injection site reaction, urticaria, upper respiratory tract infection, and stomatitis. No serious adverse events were observed.
Conclusion: This study provides evidence for the use of ixekizumab in real-world clinical practice and confirm that it is effective and safe in treating Korean patients with moderate to severe psoriasis.
|
|
KEYWORD
|
|
Korea, Psoriasis, Safety, Therapeutics
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|